Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

CVS teams up with U.S. government to administer COVID-19 antibody therapy

By Brian Buntz | December 2, 2020

CVS HealthCVS Health (NYSE:CVS), the parent of the retail pharmacy chain CVS Pharmacy, Aetna and other brands, has committed to partnering with the Trump administration to administer Eli Lilly’s (NYSE:LLY) monoclonal antibody LY-CoV555 (bamlanivimab).

The company will administer the intravenous therapy to high-risk patients in their homes or long-term care facilities. 

In the pilot program, CVS will administer 1,000 doses of the treatment in seven metropolitan areas surrounding Boston, Chicago, Cleveland, Los Angeles, Milwaukee, Minneapolis and Tampa over the next three months. 

The program will make the drug available to qualifying patients at no cost to them.  

After the pilot concludes, the U.S. government could potentially extend the program for an additional three months. 

HHS announced in late October that it planned on allocating 300,000 doses of the antibody treatment. 

FDA granted an emergency use authorization (EUA) to the treatment in November. 

The agency also granted an EUA for the combination of Lilly’s Olumiant and Gilead’s (NSDQ: GILD) Remdesivir for hospitalized COVID-19 patients.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE